Key result
Non-invasive STAR shows promise for reducing the burden of refractory ventricular and atrial arrhythmias.
Why the study?
Existing invasive and pharmacological treatments for refractory tachyarrhythmias like AF and VT carry limited control rates, side effects, and high relapse rates, highlighting the need for novel non-invasive alternatives.
Does stereotactic arrhythmia radioablation (STAR) improve outcomes in patients with refractory tachyarrhythmias?
Does stereotactic arrhythmia radioablation (STAR) improve outcomes in patients with refractory tachyarrhythmias?
Answers are grounded in this paper and cite their sources.
STAR represents a promising, non-invasive therapeutic option for patients with refractory ventricular tachycardia and atrial fibrillation who fail conventional therapies.
Tachyarrhythmias are common cardiovascular emergencies encountered in clinical practice. Among these, atrial fibrillation (AF) and ventricular tachycardia (VT) pose significant hazards due to their prevalence and severity. Initially, non-invasive pharmacological antiarrhythmic interventions were the primary treatment modality; however, due to their limited control rates and side effects, invasive therapies have been introduced in recent years. These include catheter ablation, alcohol ablation, cardiac implantable electronic devices, and heart transplantation. Nonetheless, for some patients, invasive treatments do not offer a definitive cure for arrhythmias and carry the risk of recurrence, especially with AF and VT, where the relapse rates are high and the treatment for VT is correlated with the type of tachycardia present. Currently, novel non-invasive treatment methods are emerging, with stereotactic radioablation therapy becoming an effective alternative for the management of refractory tachyarrhythmias. This review provides an overview of the application background of Stereotactic Arrhythmia Radioablation (STAR) therapy and promising results from its use in animal models and clinical applications.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) conducted a review in Arrhythmias (Ventricular Tachycardia and Atrial Fibrillation). Stereotactic arrhythmia radioablation (STAR) was evaluated. Stereotactic arrhythmia radioablation (STAR) is an emerging non-invasive therapy that shows promise in reducing the burden of refractory ventricular and atrial arrhythmias, though long-term efficacy and safety require further investigation.
Synapse has enriched 10 related papers. Consider them for comparative context: